Antidote TechnologyDigital patient engagement company, Inc., has announced a partnership with SEQSTER, a multidimensional healthcare data platform, to identify patients for clinical trials and improve trial timelines.
Antidote provides a patient recruitment platform for clinical trials, including patient screening and support services.
The company will leverage SEQSTER’s operating system to better match patients with clinical trials based on their genomic data, lifestyle factors and medical history.
“Our partnership with SEQSTER will enable us to augment our precision recruitment processes with unparalleled data integration capabilities to more effectively identify suitable participants and accelerate time to market for new therapies,” Antidote co-CEO Samantha Beck said in a statement.
Larger trends
In December, San Diego-based SEQSTER partnered with Palo Alto-based Real World Data Platform. Atropos Health improves diversity and inclusion in clinical trials by creating turnkey patient registries to accelerate evidence generation.
In March, SEQSTER partnered with the National Multiple Sclerosis Society to use data to connect multiple sclerosis patients, researchers and care centers across the country.
Three months later, the decentralized clinical trial company Thread and SEQSTER partner to provide access to real-world data for life sciences companies, researchers, and patients.
Another company focused on improving the clinical trial experience is an oncology-focused digital health company. Flatiron Health, which Roche acquired in 2018.
May, Flatiron Announced a strategic collaboration with the Association of Cancer Care Centers to promote access to clinical trials in local communities, improve clinical trial efficiency, and enhance collection of study-related data.
Clinical Trial Start-Up Inato, the Digital Medicine Institute (DiMe), clinical trial technology company Science 37 and tech-enabled clinical trials platform Paradigm are also players in the space.
